US 12,168,036 B2
Methods for treating angiogenic eye disorders with high doses of VEGF receptor fusion proteins
Kenneth S. Graham, Pleasant Valley, NY (US); and Saurabh Wadhwa, Nanuet, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Jul. 23, 2021, as Appl. No. 17/384,070.
Application 17/384,070 is a continuation of application No. 16/409,631, filed on May 10, 2019, granted, now 11,103,552.
Claims priority of provisional application 62/813,882, filed on Mar. 5, 2019.
Claims priority of provisional application 62/769,876, filed on Nov. 20, 2018.
Claims priority of provisional application 62/752,127, filed on Oct. 29, 2018.
Claims priority of provisional application 62/669,506, filed on May 10, 2018.
Prior Publication US 2021/0353714 A1, Nov. 18, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/17 (2006.01); A61K 9/00 (2006.01); A61K 38/18 (2006.01); A61K 47/12 (2006.01); A61K 47/18 (2017.01); A61K 47/22 (2006.01); A61K 47/26 (2006.01); A61P 27/02 (2006.01); C07K 14/71 (2006.01)
CPC A61K 38/179 (2013.01) [A61K 9/0048 (2013.01); A61K 47/12 (2013.01); A61K 47/183 (2013.01); A61K 47/22 (2013.01); A61K 47/26 (2013.01); A61P 27/02 (2018.01)] 38 Claims
 
1. A method for treating an angiogenic eye disorder in a human subject in need thereof comprising administering, intravitreally into an eye of the subject, in a volume of about 100 microliters or less, at least about 8 mg of a VEGF receptor fusion protein comprising two polypeptides that comprise an immunoglobulin-like (Ig) domain 2 of VEGFR1, an Ig domain 3 of a VEGFR2, and a multimerizing component; wherein the VEGF receptor fusion protein is in an aqueous pharmaceutical formulation comprising at least 100 mg/ml of the VEGF receptor fusion protein and having a viscosity of about 5-15 centiPoise (cP) at 20° C.